SG11201803654TA - Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same - Google Patents
Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using sameInfo
- Publication number
- SG11201803654TA SG11201803654TA SG11201803654TA SG11201803654TA SG11201803654TA SG 11201803654T A SG11201803654T A SG 11201803654TA SG 11201803654T A SG11201803654T A SG 11201803654TA SG 11201803654T A SG11201803654T A SG 11201803654TA SG 11201803654T A SG11201803654T A SG 11201803654TA
- Authority
- SG
- Singapore
- Prior art keywords
- uveitis
- compositions
- treatment
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562250269P | 2015-11-03 | 2015-11-03 | |
EP16306166 | 2016-09-14 | ||
US201662408391P | 2016-10-14 | 2016-10-14 | |
PCT/US2016/060344 WO2017079443A1 (en) | 2015-11-03 | 2016-11-03 | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803654TA true SG11201803654TA (en) | 2018-05-30 |
Family
ID=57018106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803654TA SG11201803654TA (en) | 2015-11-03 | 2016-11-03 | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
Country Status (12)
Country | Link |
---|---|
US (2) | US10968278B2 (zh) |
EP (1) | EP3371224A1 (zh) |
JP (3) | JP7272794B2 (zh) |
KR (1) | KR20180073680A (zh) |
CN (1) | CN108473583A (zh) |
AU (2) | AU2016348418B8 (zh) |
BR (1) | BR112018008900A8 (zh) |
CA (1) | CA3003874A1 (zh) |
MX (2) | MX2018005589A (zh) |
SG (1) | SG11201803654TA (zh) |
TW (3) | TWI786636B (zh) |
WO (1) | WO2017079443A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
CA3003874A1 (en) | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
WO2020047029A1 (en) | 2018-08-29 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
US11498969B2 (en) | 2019-01-31 | 2022-11-15 | Sanofi Biotechnology | Compositions and methods for treating juvenile idiopathic arthritis |
JP2022537555A (ja) | 2019-06-20 | 2022-08-26 | 武田薬品工業株式会社 | ウイルスベースの遺伝子療法による治療方法 |
WO2024088921A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Predicting response to il-6 antagonists |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100249937B1 (ko) | 1991-04-25 | 2000-04-01 | 나가야마 오사무 | 인간 인터루킨-6 수용체에 대한 재구성 인간 항체 |
PL186506B1 (pl) | 1994-10-07 | 2004-01-30 | Chugai Pharmaceutical Co Ltd | Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała |
US6046223A (en) | 1996-02-26 | 2000-04-04 | Advanced Research & Technology Institute | Treatment of macular edema |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
CA2565714C (en) | 2004-05-06 | 2014-12-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
US8080248B2 (en) * | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
AU2009246430B2 (en) * | 2008-05-13 | 2015-07-02 | Novimmune S.A. | Anti-IL-6/IL-6R antibodies and methods of use thereof |
SG2014014724A (en) | 2010-05-07 | 2014-07-30 | Xoma Technology Ltd | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS |
TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
SG10201608703SA (en) * | 2012-11-08 | 2016-12-29 | Eleven Biotherapeutics Inc | Il-6 antagonists and uses thereof |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
EP3071230B1 (en) | 2013-11-22 | 2020-04-08 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
CA3003874A1 (en) | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
-
2016
- 2016-11-03 CA CA3003874A patent/CA3003874A1/en active Pending
- 2016-11-03 CN CN201680077216.5A patent/CN108473583A/zh active Pending
- 2016-11-03 MX MX2018005589A patent/MX2018005589A/es unknown
- 2016-11-03 WO PCT/US2016/060344 patent/WO2017079443A1/en active Application Filing
- 2016-11-03 US US15/342,833 patent/US10968278B2/en active Active
- 2016-11-03 SG SG11201803654TA patent/SG11201803654TA/en unknown
- 2016-11-03 TW TW110117779A patent/TWI786636B/zh active
- 2016-11-03 KR KR1020187015533A patent/KR20180073680A/ko not_active Application Discontinuation
- 2016-11-03 TW TW111143328A patent/TW202339795A/zh unknown
- 2016-11-03 EP EP16810513.8A patent/EP3371224A1/en active Pending
- 2016-11-03 JP JP2018543040A patent/JP7272794B2/ja active Active
- 2016-11-03 TW TW105135684A patent/TWI729022B/zh active
- 2016-11-03 BR BR112018008900A patent/BR112018008900A8/pt not_active Application Discontinuation
- 2016-11-03 AU AU2016348418A patent/AU2016348418B8/en active Active
-
2018
- 2018-05-03 MX MX2022011972A patent/MX2022011972A/es unknown
-
2021
- 2021-02-24 US US17/183,904 patent/US20210301027A1/en active Pending
- 2021-09-10 JP JP2021147378A patent/JP2021193120A/ja active Pending
-
2023
- 2023-02-15 JP JP2023021270A patent/JP2023062062A/ja active Pending
- 2023-09-20 AU AU2023233110A patent/AU2023233110A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170166646A1 (en) | 2017-06-15 |
BR112018008900A8 (pt) | 2019-02-26 |
AU2023233110A1 (en) | 2023-10-05 |
JP2023062062A (ja) | 2023-05-02 |
AU2016348418B8 (en) | 2023-10-19 |
JP7272794B2 (ja) | 2023-05-12 |
TW201729828A (zh) | 2017-09-01 |
MX2022011972A (es) | 2022-10-20 |
CN108473583A (zh) | 2018-08-31 |
EP3371224A1 (en) | 2018-09-12 |
KR20180073680A (ko) | 2018-07-02 |
TWI786636B (zh) | 2022-12-11 |
TW202339795A (zh) | 2023-10-16 |
AU2016348418A1 (en) | 2018-06-21 |
JP2018532804A (ja) | 2018-11-08 |
BR112018008900A2 (pt) | 2018-11-06 |
WO2017079443A8 (en) | 2017-07-06 |
AU2016348418B2 (en) | 2023-10-12 |
AU2016348418A8 (en) | 2023-10-19 |
US20210301027A1 (en) | 2021-09-30 |
WO2017079443A1 (en) | 2017-05-11 |
JP2021193120A (ja) | 2021-12-23 |
US10968278B2 (en) | 2021-04-06 |
CA3003874A1 (en) | 2017-05-11 |
MX2018005589A (es) | 2018-11-09 |
TWI729022B (zh) | 2021-06-01 |
TW202138001A (zh) | 2021-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201907815B (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses | |
IL272367A (en) | Antibodies against CD39, compositions containing antibodies against CD39 and methods of using antibodies against CD39 | |
HRP20192145T1 (hr) | Pripravci nosača-antitijela i metode pripreme i uporabe istih | |
DK3889145T3 (da) | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme | |
ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
SG11201803654TA (en) | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same | |
HK1259372A1 (zh) | 治療化合物、其組合物及使用方法 | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
HK1247789A1 (zh) | 用於治療水腫的組合物和方法 | |
PT3204038T (pt) | Composições que compreendem amilase para utilização no tratamento do prurido | |
ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
HK1247136A1 (zh) | 包含15-hepe的組合物和其使用方法 | |
HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 | |
PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
IL251588A0 (en) | Methods and preparations for increasing the potency of antifungal agents | |
IL259064A (en) | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same | |
EP3307903C0 (en) | PROCESS FOR PREPARING KILLER-TOXINS |